Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.79 |
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954365 | 0.81 | SMN1; SMN2 (0.80) | KMT2ALMNAALDH1A1MEN1CYP1A2 | |
| SCHEMBL18711636 | 0.80 | TP53 (0.73) | KMT2ALMNAALDH1A1MEN1CYP1A2 | |
| SCHEMBL18702153 | 0.78 | TP53 (0.71) | KMT2ALMNAALDH1A1MEN1CYP1A2 | |
| SCHEMBL195773 | 0.78 | KMT2A (0.67) | KMT2ALMNAALDH1A1MEN1CYP1A2 | |
| SCHEMBL10016542 | 0.76 | SMN1; SMN2 (1.00) | KMT2ALMNAALDH1A1MEN1CYP1A2 | |
| SCHEMBL7023347 | 0.74 | SMN1; SMN2 (0.68) | KMT2ALMNAALDH1A1MEN1CYP1A2 | |
| SCHEMBL13254370 | 0.74 | KMT2A (0.65) | KMT2ALMNAALDH1A1MEN1CYP1A2 | |
| SCHEMBL6392857 | 0.74 | KMT2A (0.60) | KMT2ALMNAALDH1A1MEN1CYP1A2 | |
| SCHEMBL12656093 | 0.72 | L3MBTL1 (0.72) | KMT2AALDH1A1MEN1SMN1; SMN2GAA | |
| SCHEMBL2805271 | 0.72 | MAPK1 (0.61) | KMT2ALMNAALDH1A1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6649603-B2 | For therapy of metabolic disorders related to insulin resistance or hyperglycemia | WYETH | 2003-11-18 | — | — | US | disclosed |
| EP-1328512-A2 | CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030027797-A1 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | WYETH (US) | 2003-02-06 | — | — | US | disclosed |
| US-6498170-B2 | 4-((2S)-3-(1-(4-BUTOXY-BENZENESULFONYL)-AZETIDIN-3-YLAMINO)-2 -HYDROXY- PROPOXY)-PHENOL FOR EXAMPLE; HYPOGLYCEMIC AGENT; INCREASING LEAN MEAT TO FAT RATIO IN MAMMALS | WYETH | 2002-12-24 | — | — | US | disclosed |
| US-20020022605-A1 | Cyclamine sulfonamides as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-21 | — | — | US | disclosed |
| WO-2002006221-A2 | CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022605-A1 | Cyclamine sulfonamides as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | KMT2A 2355/4885LMNA 2544/4885ALDH1A1 3013/4885 |
| US-20030027797-A1 | Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | KMT2A 2051/4885LMNA 2363/4885ALDH1A1 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.